BR112012020557A8 - formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio - Google Patents

formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio

Info

Publication number
BR112012020557A8
BR112012020557A8 BR112012020557A BR112012020557A BR112012020557A8 BR 112012020557 A8 BR112012020557 A8 BR 112012020557A8 BR 112012020557 A BR112012020557 A BR 112012020557A BR 112012020557 A BR112012020557 A BR 112012020557A BR 112012020557 A8 BR112012020557 A8 BR 112012020557A8
Authority
BR
Brazil
Prior art keywords
benzazepin
pyrimido
methoxybenzoate
fluoro
chloro
Prior art date
Application number
BR112012020557A
Other languages
English (en)
Other versions
BR112012020557A2 (pt
Inventor
Armitage Ian
D Eddleston Mark
I Cooper Martin
C Faiber Neil
J Mccubbin Quentin
W Watt Stephen
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BR112012020557A2 publication Critical patent/BR112012020557A2/pt
Publication of BR112012020557A8 publication Critical patent/BR112012020557A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

formas cristalinas de sódio 4 - [{9-cloro-7-(2-fluoro-6-metaxifenil)-5h-pirimido [5,4-d] [2] benzazepina-2-il]-amino}-2-metoxibenzoato. a presente invenção é dirigida a um composto de fórmula (z): ou uma forma cristalina do mesmo, ou um solvato do mesmo; a uma composição farmacêutica sólida compreendendo uma quantidade farmaceuticamente eficaz do composto de fórmula (i), ou uma forma cristalina do mesmo,ou um solvato do mesmo, e pelo menos um transportador ou diluente farmaceuticamente aceitável, e com o uso de um composto de fórmula (j), ou uma forma cristalina do mesmo, ou um solvato do mesmo, para o tratamento de um paciente sofrendo de, ou indivíduo, uma doença, distúrbio, ou condição mediada por aurora quinase, e métodos relacionados a este.
BR112012020557A 2010-02-19 2011-02-15 formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio BR112012020557A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30604710P 2010-02-19 2010-02-19
PCT/US2011/024883 WO2011103089A1 (en) 2010-02-19 2011-02-15 Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate

Publications (2)

Publication Number Publication Date
BR112012020557A2 BR112012020557A2 (pt) 2015-12-08
BR112012020557A8 true BR112012020557A8 (pt) 2018-01-02

Family

ID=44483264

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012020557A BR112012020557A8 (pt) 2010-02-19 2011-02-15 formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio

Country Status (8)

Country Link
US (3) US8653064B2 (pt)
EP (1) EP2536279A4 (pt)
JP (2) JP2013520424A (pt)
CN (2) CN102770024A (pt)
BR (1) BR112012020557A8 (pt)
CA (1) CA2788774A1 (pt)
RU (1) RU2012140021A (pt)
WO (1) WO2011103089A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5738196B2 (ja) 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN102770024A (zh) 2010-02-19 2012-11-07 米伦纽姆医药公司 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式
TW201316991A (zh) 2011-06-03 2013-05-01 Millennium Pharm Inc Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103724350A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CN103408552B (zh) * 2013-07-25 2015-07-01 苏州明锐医药科技有限公司 阿立塞替的制备方法
CN103408551B (zh) * 2013-07-25 2015-08-05 苏州明锐医药科技有限公司 阿立塞替的制备方法
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
IL59316A (en) 1979-02-07 1983-07-31 Sparamedica Ag Phenylpyrimidobenzazepine derivatives,their preparation and pharmaceutical compositions containing them
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IL126095A0 (en) 1996-03-08 1999-05-09 Zeneca Ltd Azolobenzazepine derivatives as neurogically active agents
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
ATE233764T1 (de) 1997-09-29 2003-03-15 Meiji Seika Kaisha Tricyclische triazolobenzazepinderivate, verfahren zu ihrer herstellung und antiallergische mittel
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
JP2003513012A (ja) 1999-08-11 2003-04-08 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
CN100418955C (zh) 2001-08-09 2008-09-17 埃科特莱茵药品有限公司 新型苯并稠杂环
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CN101014603B (zh) * 2004-05-14 2014-08-20 千禧药品公司 通过抑制极光激酶抑制有丝***的化合物和方法
MXPA06013042A (es) 2004-05-14 2007-02-12 Millennium Pharm Inc Compuestos y m??todos para inhibir la progresion mit??tica.
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
US20070104785A1 (en) 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
MX2008008320A (es) 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
EP2037919A2 (en) 2006-06-30 2009-03-25 Schering Corporation Method of using substituted piperidines that increase p53 activity
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
JP5738196B2 (ja) 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN102770024A (zh) 2010-02-19 2012-11-07 米伦纽姆医药公司 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式

Also Published As

Publication number Publication date
JP2015180679A (ja) 2015-10-15
US20170190706A1 (en) 2017-07-06
BR112012020557A2 (pt) 2015-12-08
CN102770024A (zh) 2012-11-07
US20140357622A1 (en) 2014-12-04
RU2012140021A (ru) 2014-03-27
EP2536279A4 (en) 2013-07-24
WO2011103089A1 (en) 2011-08-25
JP2013520424A (ja) 2013-06-06
CN104031049A (zh) 2014-09-10
US20110245234A1 (en) 2011-10-06
US10017513B2 (en) 2018-07-10
EP2536279A1 (en) 2012-12-26
US8653064B2 (en) 2014-02-18
CA2788774A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
BR112012020557A8 (pt) formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
CR10419A (es) Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios
BR112015023412A8 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
GEP20156348B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
BR112013014184A2 (pt) compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
CO6150162A2 (es) Pirrolopirimidinas para composiciones farmaceuticas
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
BRPI0611705A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
SI2150530T1 (sl) Substituirani sulfonamidni derivati
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
AR068919A1 (es) 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)[1,2,4]triazol-1-il]-n-etil-acetamida y analogos del mismo, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en trastornos psicoticos y/o enfermedades con dificultades intelectuales.
NO20091254L (no) Terapeutiske sammensetninger
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements